Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03475953
Recruitment Status : Recruiting
First Posted : March 23, 2018
Last Update Posted : June 17, 2019
Sponsor:
Collaborators:
Bayer
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Institut Bergonié

Brief Summary:
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (seven cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).

Condition or disease Intervention/treatment Phase
Colorectal Cancer Not MSI-H or MMR-deficient GIST Oesophageal or Gastric Carcinoma Biliary Tract Cancer Hepatocellular Carcinoma Soft-tissue Sarcoma Thyroid Cancer Gastro-enteropancreatic Neuroendocrine Tumor Drug: Phase 1 : Regorafenib Drug: Phase 1 : Avelumab Drug: Phase 2 : Regorafenib Drug: Phase 2 : Avelumab Phase 1 Phase 2

Detailed Description:

This is a multicenter, prospective open-labeled phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Regorafenib given in combination with Avelumab (no dose escalation for Avelumab) in patients with advanced digestive solid tumors followed by independent phase II trials to evaluate the association of Regorafenib at the RP2D with Avelumab in 7 cohorts of advanced or metastatic tumors :

  • Cohort A: Colorectal cancer not MSI-H or MMR-deficient
  • Cohort B: GIST
  • Cohort C: Oesophageal or gastric carcinoma
  • Cohort D: Biliary tract cancer, hepatocellular carcinoma
  • Cohort E: Soft-tissue sarcoma (STS)
  • Cohort F: Radioiodine-refractory differentiated thyroid cancer (RR-DTC)
  • Cohort G: Neuroendocrine gastroenteropancreatic tumors (GEP-NETs)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 362 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This is a multicenter, prospective open-labeled phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Regorafenib given in combination with Avelumab (no dose escalation for Avelumab) in patients with advanced solid tumors followed by 7 phase II trials to evaluate the association of Regorafenib at the RP2D with Avelumab in 7 distinct disease settings (advanced or metastatic tumors).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Actual Study Start Date : May 4, 2018
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : May 2021


Arm Intervention/treatment
Experimental: Phase 1 : Regorafenib + Avelumab
Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 1 : Regorafenib
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.

Drug: Phase 1 : Avelumab
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).

Experimental: Phase 2 : cohort A Regorafenib + Avelumab
Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort B Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort C Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort D Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort E Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort F Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.

Experimental: Phase 2 : cohort G Regorafenib + Avelumab
Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
Drug: Phase 2 : Regorafenib
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.

Drug: Phase 2 : Avelumab
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.




Primary Outcome Measures :
  1. PHASE I : Recommended phase II dose (RP2D) [ Time Frame: During the first cycle (28 days) ]
    Recommended phase II dose (RP2D) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.

  2. PHASE II (7 phase II cohorts) : Assessment of the antitumor activity of regorafenib [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab based on objective response under treatment defined as CR or PR following RECIST v1.1 criteria.


Secondary Outcome Measures :
  1. PHASE I : Maximum Tolerated Dose (MTD) [ Time Frame: During the first cycle (28 days) ]
    Maximum Tolerated Dose (MTD) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.

  2. PHASE I : Dose Limiting Toxicities (DLT) [ Time Frame: During the first cycle (28 days) ]
    Dose Limiting Toxicities (DLT) evaluated on the first cycle (Day 1 to Day 28) of regorafenib when prescribed in association with avelumab.

  3. PHASE I : Toxicity [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Toxicity graded using the common toxicity criteria from the NCI v5.

  4. PHASE I : Assessment of the antitumor activity of regorafenib - Best overall response [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of best overall response as per RECIST v1.1.

  5. PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate under treatment [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate under treatment (ORR) defined as CR or PR as per RECIST v1.1.

  6. PHASE I :Assessment of the antitumor activity of regorafenib - objective response rate [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate at 6-months (ORR) defined as CR or PR as per RECIST v1.1.

  7. PHASE I :Assessment of the antitumor activity of regorafenib - non-progression [ Time Frame: 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 6-months non-progression defined as CR, PR or SD as per RECIST v1.1

  8. PHASE I :Assessment of the antitumor activity of regorafenib - progression-free survival (PFS) [ Time Frame: 1 year ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year progression-free survival (PFS) as per RECIST v1.1.

  9. PHASE I : Assessment of the antitumor activity of regorafenib - overall survival (OS) [ Time Frame: 1 year ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year overall survival (OS) as per RECIST v1.1.

  10. PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC) [ Time Frame: Day 15 of cycle 1 (Each cycle is 28 days) ]
    PK measurement expressed as Area Under Curve (AUC) for regorafenib.

  11. PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC) [ Time Frame: Day 1 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as Area Under Curve (AUC) for regorafenib.

  12. PHASE I :Pharmacocinetics (PK) - Area Under Curve (AUC) [ Time Frame: Day 15 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as Area Under Curve (AUC) for regorafenib.

  13. PHASE I :Pharmacocinetics (PK) - half-life for regorafenib. [ Time Frame: Day 15 of cycle 1 (Each cycle is 28 days) ]
    PK measurement expressed as half-life for regorafenib.

  14. PHASE I :Pharmacocinetics (PK) - half-life for regorafenib. [ Time Frame: Day 1 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as half-life for regorafenib.

  15. PHASE I :Pharmacocinetics (PK) - half-life for regorafenib. [ Time Frame: Day 15 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as half-life for regorafenib.

  16. PHASE I :PK - concentration peak for regorafenib. [ Time Frame: Day 15 of cycle 1 (Each cycle is 28 days) ]
    PK measurement expressed as concentration peak for regorafenib

  17. PHASE I :PK - concentration peak for regorafenib. [ Time Frame: Day 1 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as concentration peak for regorafenib

  18. PHASE I :PK - concentration peak for regorafenib. [ Time Frame: Day 15 of cycle 2 (Each cycle is 28 days) ]
    PK measurement expressed as concentration peak for regorafenib

  19. Phase I: Predictive blood biomarkers analysis (cytokines levels) by ELISA. [ Time Frame: day 1 of cycles 1, 2, 4, 6 and at progression ]
    levels of angiogenic and immunologic biomarkers in blood

  20. Phase I: Predictive blood biomarkers analysis (lymphocytes) by flow cytmetry. [ Time Frame: day 1 of cycles 1, 2, 4, 6 and at progression ]
    levels of angiogenic and immunologic biomarkers in blood

  21. Phase I: Predictive tumor growth factor biomarkers analysis by immunohistochemistry. [ Time Frame: day 1 of cycle 1 and day 1 of cycle 2 ]
    levels of angiogenic and immunologic biomarkers in tissue

  22. Phase I: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab. [ Time Frame: throughouth the treatment period, an average of 6 months ]
    Toxicity graded using the common toxicity criteria from the NCI v5.

  23. PHASE II : Assessment of the antitumor activity of regorafenib - Best overall response [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of best overall response as per RECIST v1.1.

  24. PHASE II : Assessment of the antitumor activity of regorafenib - objective response rate [ Time Frame: Throughout the treatment period, an average of 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of objective response rate at 6-months (ORR) defined as CR or PR as per RECIST v1.1.

  25. PHASE II :Assessment of the antitumor activity of regorafenib - non progression [ Time Frame: 6 months ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 6-months non-progression defined as CR, PR or SD as per RECIST v1.1.

  26. PHASE II : Assessment of the antitumor activity of regorafenib - Progression-Free Survival (PFS) [ Time Frame: 1 year ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year progression-free survival (PFS) as per RECIST v1.1.

  27. PHASE II : Assessment of the antitumor activity of regorafenib - Overall Survival [ Time Frame: 1 year ]
    Assessment of the antitumor activity of regorafenib when prescribed in association with avelumab in terms of 1-year overall survival (OS) as per RECIST v1.1.

  28. Phase II: Predictive blood biomarkers analysis (cytokines levels) by ELISA. [ Time Frame: day 1 of cycles 1, 2, 4, 6 and at progression ]
    levels of angiogenic and immunologic biomarkers in blood

  29. Phase II: Predictive blood biomarkers analysis (lymphocytes) by flow cytometry. [ Time Frame: day 1 of cycles 1, 2, 4, 6 and at progression ]
    levels of angiogenic and immunologic biomarkers in blood

  30. Phase II: Predictive tumor growth factor biomarkers analysis by immunohistochemistry. [ Time Frame: day 1 of cycle 1 and day 1 of cycle 2 ]
    levels of angiogenic and immunologic biomarkers in tissue

  31. Phase II: Adverses events graded using the common toxicity criteria from the NCI v5 to determine the safety profile of regorafenib plus avelumab [ Time Frame: throughouth the treatment period, an average of 6 months ]
    Toxicity graded using the common toxicity criteria from the NCI v5

  32. Predictive metabolomic analysis by liquid chromatography-mass spectrometry [ Time Frame: day 1 of cycles 1, 2, 4, 6 and at progression ]
    Levels of metabolites in blood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria :

  1. Histology:

    • Dose escalation part: histologically confirmed non MSI-H or deficient-MMR colorectal cancer, or GIST, or esophageal or gastric carcinoma or hepatobiliary cancers,
    • Phase II trials : histologically confirmed

      • non MSI-H or deficient-MMR colorectal cancer (cohort A),
      • or GIST (cohort B). As recommended diagnosis by INCa, patients with GIST must have histologically confirmed by central review, except if it has been already confirmed by the RRePS Network
      • or esophageal or gastric carcinoma (cohort C),
      • or hepatobiliary cancers (cohort D),
      • or soft-tissue sarcoma (STS) (cohort E). As recommended diagnosis by INCa, patients with STS must have histologically confirmed by central review, except if it has been already confirmed by the RRePS Network
      • or radioiodine-refractory differentiated thyroid cancer [RR-DTC] (cohort F),
      • or neuroendocrine gastroenteropancreatic tumors grade 2 and 3 As recommended diagnosis by INCa, patients with GIST must have histologically confirmed by central review, except if it has been already confirmed by the RRePS Network.
  2. Advanced non resectable / metastatic disease,
  3. Patients for which either there is no further established therapy that is known to provide clinical benefit, OR (for patients to be treated with 160 mg regorafenib) regorafenib monotherapy is an approved or established therapeutic option,
  4. Age ≥ 18 years,
  5. ECOG, Performance status ≤ 1,
  6. Measurable disease according to RECIST (outside any previously irradiated field). At least one site of disease must be uni-dimensionally ≥ 10 mm,
  7. Life expectancy > 3 months,
  8. ≥ 1 previous line (s) of systemic therapy,
  9. Adequate hematological, renal, metabolic and hepatic functions:

    1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell [RBC] transfusion, if clinically indicated); absolute neutrophil count (ANC) ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l, lymphocytes ≥ 1000/mm3.
    2. Alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (ASP) ≤ 2.5 x upper limit of normality (ULN) (≤ 5 in case of extensive skeletal involvement for AP exclusively and ≤ 5 x ULN in case of liver metastasis for AST and ALT).
    3. Total bilirubin ≤ 1.5 x ULN.
    4. Albumin ≥ 25g/l.
    5. Calculated creatinine clearance (CrCl) ≥ 30 ml/min (according to Cockroft and Gault formula).
    6. Creatine phosphokinase (CPK) ≤ 2.5 x ULN.
    7. INR < 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
    8. aPTT ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
    9. Lipase ≤ 1.5 X ULN.
    10. Cohort specific criteria: Patients with hepatocellular carcinoma must have a correct hepatocellular function, id est Child-Pugh A.
  10. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
  11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy,
  12. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment, excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, version 5.0)),
  13. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication,
  14. Both women and men must agree to use an highly effective method of contraception throughout the treatment period and for eight weeks after discontinuation of treatment. Acceptable methods for contraception are described in protocol section 7.4.1,
  15. Voluntary signed and dated written informed consents prior to any specific study procedure,
  16. Patients with a social security in compliance with the French law.
  17. Documented disease progression (as per RECIST v1.1) before study entry. For patients of cohort E (STS): this progression will be confirmed by central review on the basis of two CT scan or MRI obtained not less than 6 months in the period of 12 months prior to inclusion. For patients of cohort F (RR-DTC): this progression will be confirmed by central review on the basis of two CT scan or MRI obtained at less than 12 months prior to inclusion.
  18. For patient with RR-DTC (cohort F): patients must have received prior first line therapy with an anti-VEGF

Exclusion Criteria:

  1. Previous treatment with Avelumab or Regorafenib,
  2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti- CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways),
  3. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal metastases,
  4. Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding,
  5. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  6. Previous enrolment in the present study,
  7. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,
  8. Known hypersensitivity to any involved study drug or of its formulation components,
  9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent :

    1. Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
    2. Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
    3. Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable
  10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,
  11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan or interstitial lung disease with ongoing signs and symptoms at inclusion. History of radiation pneumonitis in the radiation field (fibrosis) is permitted,
  12. Has known active hepatitis B or hepatitis C,
  13. Has a known history of Human Immunodeficiency Virus (HIV) (HIV1/2 antibodies) or known acquired immunodeficiency syndrome (AIDS),
  14. Persistent proteinuria < 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (≥ Grade 3, NCI-CTCCAE v 5.0),
  15. Major surgical procedure or significant traumatic injury within 28 days before start of study medication,
  16. Non-healing wound, non-healing ulcer, or non-healing bone fracture,
  17. Patients with evidence or history of any bleeding diathesis, irrespective of severity,
  18. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication,
  19. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication),
  20. Ongoing infection > Grade 2 as per NCI CTCAE v5.0,
  21. Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management,
  22. Congestive heart failure ≥ New York Heart Association (NHYA) class 2,
  23. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),
  24. Myocardial infarction less than 6 months bedfore start of study drug,
  25. Uncontrolled cardiac arrhythmias,
  26. Pregnant or breast-feeding patients,
  27. Individuals deprived of liberty or placed under legal guardianship,
  28. Prior organ transplantation, including allogeneic stem-cell transplantation,
  29. Known alcohol or drug abuse,
  30. Vaccination within 4 weeks of the first dose of Avelumab and while on trial is prohibited except for administration of inactivated vaccines,
  31. Patients with any condition that impairs their ability to swallow and retain tablets,
  32. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study,
  33. Patient with oral anticoagulation therapy,
  34. Suspected or known intraabdominal fistula.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03475953


Contacts
Layout table for location contacts
Contact: Sophie COUSIN, MD +33 5.56.33.33.33 s.cousin@bordeaux.unicancer.fr
Contact: Simone MATHOULIN-PELISSIER, MD, PhD s.mathoulin@bordeaux.unicancer.fr

Locations
Layout table for location information
France
Institut Bergonié Recruiting
Bordeaux, France, 33076
Contact: Sophie COUSIN, MD         
Principal Investigator: Sophie COUSIN, MD         
Sub-Investigator: Antoine ITALIANO, MD, PhD         
Centre Hospitalier Régional Universitaire - CHU Morvan Not yet recruiting
Brest, France, 29200
Contact: Jean-Philippe METGES, MD, PhD         
Centre Léon Bérard Not yet recruiting
Lyon, France, 69008
Contact: Philippe CASSIER, MD         
Institut de Cancérologie de Montpellier Recruiting
Montpellier, France, 34298
Contact: Antoine ADENIS, MD, PhD         
IUCT Oncopôle - Institut Claudius Regaud Recruiting
Toulouse, France, 31059
Contact: Carlos GOMEZ-ROCA, MD         
Institut Gustave Roussy Not yet recruiting
Villejuif, France, 94800
Contact: Christophe MASSARD, MD, PhD         
Sponsors and Collaborators
Institut Bergonié
Bayer
Merck KGaA, Darmstadt, Germany
Layout table for additonal information
Responsible Party: Institut Bergonié
ClinicalTrials.gov Identifier: NCT03475953    
Other Study ID Numbers: IB 2017-01
2016-005175-27 ( EudraCT Number )
First Posted: March 23, 2018    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Bergonié:
Advanced solid tumor
Metastatic tumor
Phase Ib/II trial
Colorectal cancer not MSI-H or MMR-deficient
GIST
Oesophageal or Gastric Carcinoma
Biliary Tract cancer
Hepatocellular Carcinoma
Soft-tissue sarcoma
Thyroid cancer
Neuroendocrine gastroenteropancreatic tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Colorectal Neoplasms
Sarcoma
Carcinoma, Hepatocellular
Thyroid Neoplasms
Neuroendocrine Tumors
Biliary Tract Neoplasms
Stomach Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Connective and Soft Tissue
Adenocarcinoma
Liver Neoplasms
Liver Diseases
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Head and Neck Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal